A new treatment for severe pulmonary arterial hypertension based on an old idea: inhibition of 5-lipoxygenase

Norbert F. Voelkel¹ and Marc Peters-Golden²
¹Department of Pulmonary Medicine, University of Amsterdam Medical Centers, Amsterdam, the Netherlands; ²Pulmonary and Critical Care Medicine Division, University of Michigan Medical School, Ann Arbor, MI, USA

Abstract
It has been generally accepted that severe forms of pulmonary arterial hypertension are associated with inflammation. Plasma levels in patients with severe pulmonary arterial hypertension show elevated levels of interleukins and mediators of inflammation and histologically the diseased small pulmonary arterioles show infiltrates of inflammatory and immune cells. Here, we review the literature that connects pulmonary hypertension with the arachidonic acid/5-lipoxygenase-derived leukotriens. This mostly preclinical background data together with the availability of 5-lipoxygenase inhibitors and leukotriene receptor blockers provide the rationale for testing the hypothesis that 5-lipoxygenase products contribute to the pathobiology of severe pulmonary arterial hypertension in a subgroup of patients.

Keywords
leukotrienes, inflammation, cell phenotype shift, gene transcription

Introduction
Severe pulmonary arterial hypertension (PAH) occurs as an idiopathic and sometimes hereditary process as well as one associated with congenital heart disorders, HIV infection, collagen vascular diseases, chronic liver disease, and schistosomiasis. Although PAH has not classically been regarded as an inflammatory process, the presence of inflammatory cells in vascular lesions was, in fact, recognized many years ago. Donald Heath initially brought attention to mast cells in and around pulmonary vascular lesions and lymphocytes were later documented using immunohistochemistry. Elevated blood levels of the proinflammatory cytokines IL-1 and IL-6 were reported in 1995 and it is now believed that their degree of elevation is related to clinical outcomes.

Several recent reviews have sought to consider the importance of inflammation in PAH within an overall pathobiological context. This question of “How important is inflammation?” will ultimately be answered by clinical trial data.

A series of early experimental studies linked the lung circulation and pulmonary hypertension (PH) to 5-lipoxygenase (5-LO) metabolites of arachidonic acid, particularly leukotrienes (LTs) (Table 1). Tian et al. recently reviewed the roles of LTs in PH. In this perspective, we review the history of our evolving knowledge about LTs and pulmonary vascular responses. We also consider features of the 5-LO enzyme that, though less well appreciated, suggest the possibility for novel roles in transcriptional regulation apart from its enzymatic role in generating bioactive LTs. Ultimately, we endeavor to examine the strength of the evidence which links pulmonary vascular diseases and 5-LO and to build a case for treating patients with severe forms of PAH with 5-LO inhibitors.

Corresponding author:
Norbert F. Voelkel, Amsterdam University Medical Centers, Amsterdam, the Netherlands.
Email: nfvoelkel@gmail.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). © The Author(s) 2020. Article reuse guidelines: sagepub.com/journals-permissions journals.sagepub.com/home/pul
Lipoxygenases, leukotrienes, and leukotriene receptors

Lipoxygenases (or LOs) are a group of fatty acid dioxygenase enzymes that oxidize polyunsaturated fatty acids to hydroperoxy derivatives which, in turn, are further metabolized to bioactive lipid mediators. They are also key players in the regulation of cellular redox homeostasis, itself an important modulator of gene expression. The human genome contains six LO genes, each of which encodes a distinct enzyme with specific biochemical activity. Here, we focus on 5-LO (Fig. 1), which oxygenates arachidonic acid at its C-5 carbon to first generate 5-HPETE and then LTA4. The 5-LO gene has been mapped to human chromosome 10,11 and it is worth noting that the expression level of 5-LO changes during lung development.12 A major advance was the recognition that 5-LO must work in concert with...
5-LO activating protein (FLAP), which binds and presents arachidonic acid to the oxygenase enzyme. 13,14 Under the influence of leukotriene C₄ synthase, LT₄ is glutathionylated to LTCA₄, which can be further converted to LTD₄ and then LTE₄; collectively, LTCA₄, D₄, and E₄ are termed peptido-LTs or cysteinyl-LTs (cysLTs). Mast cells and cosinophils are recognized as the major cellular sources for cysLTs. In contrast, the enzyme leukotriene A₄ hydrolase (LTAH) hydrolyzes LTAA₄ to the potent chemotactic mediator LTB₄; neutrophils and macrophages are considered the major cellular sources for LTB₄. Initially, cysLTs, in particular LTC₄, were a focus of research in pulmonary arterial responses because they were known to cause contraction of bronchi, 15 accounting for the bioactivity long known as slow-reacting substance of anaphylaxis and implicated in allergic diseases such as rhinitis and asthma.

Both cysLTs and LTB₄ exert their biological actions via multiple G protein-coupled receptors, which differ in their ligand specificity, affinity, cellular distribution, and signal transduction. Comprehensive reviews of LT biology and receptors exist; 16 for our purposes, it is sufficient to know that the major receptors mediating the classical actions of cysLTs and LTB₄, respectively, are CysLT1 and BLT1. Polymorphisms of the genes encoding both LT synthetic enzymes 17,18 as well as receptors have been described, and some of these have been investigated in cohorts of patients with atopic disorders. 19,20

Over the last four decades, the recognized biological actions of LTs have expanded well beyond smooth muscle contraction and chemotaxis, and a sampling of these can be found in references. 21–37 For example, 5-HETE and cysLTs are now recognized to stimulate cell proliferation and have been implicated in the development of colon and prostate cancer. 36,37 LTC₄ appears to be a major trigger of stress-induced oxidative damage. 21

The expression of LT biosynthetic enzymes as well as LT receptors are under the control of transcriptional and epigenetic mechanisms, in particular DNA methylation, and are themselves modulated by a variety of cytokines, growth factors like TGF beta, hormones, and inflammatory mediators. 38–41 Interestingly, there is a gender difference in the formation of leukotrienes by stimulated neutrophils: those obtained from females produce several-fold higher amounts than those from males. 39

From pulmonary vasoconstriction to pulmonary vascular remodeling

Early research in PH was dominated by investigations of the mechanism of hypoxic vasoconstriction. 42 Initially described as a pulmonary vascular reflex, 43 hypoxic vasoconstriction could be studied in isolated perfused lungs. 44,45 Because mast cells were widely recognized to synthesize and release cysLTs, 46,47 Heath’s description of mast cell hyperplasia in human lungs from patients with severe PAH 2 provided a rationale supporting the investigation of a role of LTs in PH. 44,48 and systemic hypoxia was considered a possible stimulus for mast cell degranulation. 49 A collaboration between investigators at the Cardiovascular Pulmonary Research lab at the University of Colorado and Robert Murphy, who—while on sabbatical in the lab of Bengt Samuelsson at the Karolinska Institut in Stockholm—had elucidated the structure of LTs and named them, 46 was highly productive and generated much of the foundational information on these mediators in PH. Among the key observations were that cysLTs were produced and released in lungs 44,45,50,51 during vasoconstriction, 52–54 including acute hypoxic vasoconstriction. 55 However, while Naeije et al. 56 reported that high doses of the 5-LO inhibitor diethylcarbamazine failed to inhibit acute hypoxic pulmonary hypertension in anesthetized dogs, LT synthesis inhibitors had salutary actions in rat models of chronic pulmonary hypertension. 57,58 Subsequently, other stimuli, including intravascularly presented anti-IgE antibodies, were shown to elicit release of LTs, and neutrophils and lung vessels were demonstrated to cooperate in LT generation. 59,60 A number of years later, the FLAP inhibitor MK866 was likewise demonstrated to inhibit chronic hypoxia-induced PH in rats. 61 Finally, Wright et al. 62 documented gene and protein expression of both 5-LO and FLAP in the lung endothelial cells of patients with idiopathic pulmonary arterial hypertension (IPAH). The latter finding was important because prior to this discovery, the dogma had been that endothelial cells (and indeed, other nonmyeloid cells) do not express 5-LO. While the molecular mechanisms explaining aberrant expression of LT forming enzymes in vascular cells in PAH remain to be elucidated, it is intriguing to speculate that mutual interactions between 5-LO, p53, and beta-catenin, which appear to be part of the “cancer paradigm” of severe PAH are involved.

Work conducted in the lab of Joseph Loscalzo in Boston confirmed that normal pulmonary arterial endothelial cells in culture did not express 5-LO and did not generate LTs; overexpression using adenoviral 5-LO in these cells was required to enable the production of LTB₄ and cysLTs in response to stimulation with the calcium ionophore A23187. 63 Overexpression of 5-LO worsened, while the 5-LO inhibitor zileuton and the FLAP inhibitor MK866 inhibited, the development of PH in the monocrotaline rat model of PAH. 64 Because the BMPR2 gene is the most frequently mutated gene in hereditary forms of PAH, Loscalzo's lab explored the connection between impaired BMPR2 signaling and pulmonary expression of 5-LO in the pathogenesis of PAH; BMPR2 heterozygous mice did not spontaneously develop PH, but they did so after intratracheal instillation of an adenoviral 5-LO construct. 65 Al Husseini et al. 66 studied the VEGF receptor antagonist (Sugen 5416)/chronic hypoxia rat model of severe angioblative PAH and found elevated levels of LTC₄ in the hypertensive lung tissues and also that the 5-LO inhibitor diethylcarbamazine prevented and reversed the angiobliteration in this model. The drug also partially reversed
the right ventricular hypertrophy. While there is a paucity of data on myocardial leukotriene levels, myocardial mast cell numbers increase in heart failure and one study shows increased expression of 5-LO, LTC4-synthase and the CystLT1 in biopsy tissues obtained from human ischemic myocard. In aggregate, this body of research provided a strong link between PAH and 5-LO/LTs.

**Leukotriene B4**

While the focus of attention in regards to PH and the 5-LO pathway had for many years been on cysLTs as potential mediators, a possible mechanistic role for LTB4 had never been seriously considered. This was reasonable, given the prevailing views that cysLTs were contractile actors whereas the major job description ascribed to LT4 had been neutrophil chemotaxis.

These long-held assumptions were ultimately turned on their head by elegant studies performed in the laboratory of Mark Nicolls at Stanford University. They identified LT4 as a major player in lung vascular endothelial cell apoptosis and angio-obliteration using a model in which athymic rats (lacking regulatory T-lymphocytes) are treated with Sugen 5416. This model may be particularly representative of pathogenic events in forms of severe PAH with an underlying immune disorder, such as those associated with systemic sclerosis and lupus erythematosus. In these rats, lung LT4 levels were high and bestatin – an inhibitor of LTB4 hydrolase – prevented and reversed severe PAH. Perivascular lung macrophages were identified as the major source of the overproduced LT4. Further studies revealed – quite unexpectedly – that macrophage-derived LT4 itself was the major driver of endothelial cell apoptosis. These novel preclinical findings were of obvious clinical interest and led to the randomized LIBERTY trial of treatment of patients with severe PAH with the LTA4 hydrolase inhibitor bestatin. Disappointingly, when the data were analyzed by the sponsoring drug company across the entire cohort, the bestatin treatment arm was not different from the placebo arm. Unfortunately, the study results have not yet been published.

In hindsight, two possible shortcomings afflicted the design of the LIBERTY trial. First, many of the patients enrolled were on background treatment with prostacyclin analogs, and continuous infusion of prostacycin has itself been reported to result in a reduction in the high lung tissue levels of LT4 found in PAH patients not treated with prostacycin. Second, it was not determined whether those patients enrolled in the trial actually exhibited elevated plasma LT4 levels, as is frequently the case in patients with scleroderma-associated PAH, or if those that did preferentially demonstrated a reduction with bestatin treatment. For these reasons, the LIBERTY trial failed to definitively answer the question of whether LT4 plays an important role in some patients with severe PAH. It also remains unclear whether there are immunocompetent patients with LTC4 (as opposed to LTB4)-centered forms of severe PAH.

**Does 5-LO participate in the control of gene transcription?**

Since the actions of LTs require them to be secreted by source cells into the extracellular space where they can bind to receptors on the surface of target cells, it had long been assumed that the enzymes involved in their biosynthesis would be localized at the plasma membrane. It was, therefore, quite surprising to learn that FLAP is constitutively localized at the nuclear envelope, while 5-LO translocates to this same site from a soluble resting compartment upon cell activation (reviewed in 71 and 72). LTC4 synthase is also constitutively localized to the nuclear envelope, whereas LTA4H is predominantly cytosolic. Such a pattern of localization – which has been confirmed by numerous investigators – makes it obvious that LTs are generated at or very near to the nucleus (Fig. 2). Even more surprising is the further observation that in many cell types, including alveolar macrophages, mast cells, and recruited neutrophils, the soluble compartment in which 5-LO resides in resting cells is not the cytosol, but the nucleoplasm. In resting alveolar macrophages, immunoelectron microscopic visualization localized most nuclear 5-LO to the euchromatin region of the nucleus – the zone containing chromosomes.

![Fig. 2. The nucleus as a site of LT biosynthesis and potential actions.](image)
uncoiled to permit active gene transcription – rather than in the heterochromatin region containing coiled sections of chromosomes. Upon cell activation resulting in LT biosynthesis, 5-LO redistributed from the euchromatin region to the inner membrane of the nuclear envelope. This observation fueled the speculation that 5-LO could be participating in the regulation of transcriptional phenomena in a noncanonical manner independent of its enzymatic actions (see the recent review by Haefner et al.75 and Fig. 2). Using an immunoprecipitation strategy, Frank Fitzpatrick and Robert Lepley did identify 5-LO bound to the transcription factor protein NFkB,76 which is known to be of critical importance for the transcription of a number of genes encoding cytokines and other mediators of inflammation. Moreover, a role for NFkB has been described in models of PAH.77–80 Further investigative efforts are necessary to clarify the intriguing question of whether there is an enzyme activity-independent role for 5-LO as a transcriptional regulator.

**5-Lipoxygenase and the pulmonary hypertension-cancer overlap**

Apoptosis-resistant cell growth, phenotypic switching of cells, inflammation, angiogenesis, and participation of stem cells are hallmarks that are shared between cancer and angio-obliterative forms of severe PAH. One view is that in severe angiproliferative PAH wound healing has gone awry. Harold Dvorak has called cancer “the wound that never heals.” In this context, it is of interest that 5-LO, together with heme oxygenase 1, also plays a critical role in wound healing.81 Recent publications confirm expression of 5-LO in cancer tissues,82–84 associate cysLT receptor signaling with tumor angiogenesis and metastasis,85 and demonstrate that inhibition of 5-LO inhibits cell growth in chronic myeloid leukemia86 and in solid tumors.87,88 One recent study has described p53-dependent expression of 5-LO89 and induction of apoptosis of prostate cancer cells by 5-LO inhibition.90 Clearly, however, the nature of the relationship between 5-LO or LTs and apoptosis is complex and likely cell-specific, as we have noted previously that LTB4 promotes pulmonary endothelial cell apoptosis.91 In contrast, apoptotic cancer cells suppress 5-LO in tumor-associated macrophages.91 Clinical trials that evaluate the efficacy of 5-LO inhibitors in cancer patients are largely lacking.

**Summary and conclusion**

The preclinical data obtained in PH are clear and consistent: LTs are generated in the human lung92 and by the “sick lung circulation,”93 and inhibitors of 5-LO abrogate the development of PAH in animal models. Without doubt, chronic inflammation is a salient contributing factor to the remodeling seen in hypertensive pulmonary vessels. Additionally, the key enzymatic components required for LT synthesis – 5-LO, FLAP, and LTA₄ hydrolase – are expressed in the lung vessels from patients with severe PAH.62,69

A small study conducted with patients diagnosed with COPD and cor pulmonale found that oral administration of the cysLT1 receptor blocker zafirlukast acutely lowered the pulmonary arterial pressure on average by 23%.94 There is a convincing rationale for designing and conducting additional clinical trials testing drugs acting on the 5-LO pathway in patients with severe forms of PAH. These may include drugs inhibiting the 5-LO itself, which has the advantage of blocking production of both LTB4 and cysLTs. Alternatively, antagonists of cysLT and/or BLT receptors could be considered. Some drugs exhibiting pertinent actions are already available and could be repurposed; e.g., zileuton, diethylcarbamazine, montelukast, and zafirlukast.95 Other drugs have been developed by pharmaceutical companies for other indications but were never marketed. The risk/benefit ratio using these agents is likely to be acceptable, and at least in the case of 5-LO inhibitors, dose titration of these drugs in such trials can be guided by measuring plasma and urinary levels of LT metabolites. However, while the expression of 5-LO and of LTA₄ hydrolase in the vascular lesions of patients with IPAH can be seen as a reflection of the cells’ phenotypic shift and suggestive that 5-LO metabolic products are directly or indirectly involved in the pathobiology, it remains to be validated that plasma or urinary levels of LT metabolites accurately reflect LT synthesis by and release from the sick lung circulation.

The community of PH investigators and clinicians has begun to realize the need to transition from treatment of the disease with vasodilator drugs to testing new drugs designed to achieve disease modification. The repurposing of inhibitors acting on LT synthesis and actions and designing clinical trials to test whether there exists a 5-LO endotype of severe PAH appear to be justified, as these drugs have the potential to modify the pathobiology of severe PAH. Our patients deserve such trials to be pursued. For a first proof of concept trial, it would be preferred to enroll incident PAH patients that have been selected because they demonstrate significantly elevated plasma or urine LTC₄ or LTB₄ levels. A placebo control arm may not be necessary as long as the investigators monitor the leukotriene levels. Nonresponders would be identified as patients where 5-LO inhibition, i.e., clear reduction of leukotriene levels had been accomplished, did not result in clinical improvement.

**Authors’ contribution**

Both authors contributed equally to the writing.

**Conflict of interest**

The author(s) declare that there is no conflict of interest.

**Funding**

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
References

1. Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. *Eur Respir J* 2019; 44: 1801913.

2. Williams A, Heath D, Kay JM, et al. Lung mast cells in rats exposed to acute hypoxia, and chronic hypoxia with recovery. *Thorax* 1977; 32: 287–295.

3. Tuder RM, Groves B, Badesch DB, et al. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. *Am J Pathol* 1994; 144: 275–285.

4. Humbert M, Monti G, Brenot F, et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. *Am J Respir Crit Care Med* 1995; 151: 1628–1631.

5. Soon E, Holmes AM, Treacy CM, et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. *Circulation* 2010; 122: 920–927.

6. Hassoun PM, Mouthon L, Barberá JA, et al. Inflammation, growth factors, and pulmonary vascular remodeling. *J Am Coll Cardiol* 2009; 54: S10–S19.

7. Nicolls MR and Voelkel NF. The roles of immunity in the prevention and evolution of pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2017; 195: 1292–1299.

8. Rabinovitch M, Guignabert C, et al. Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. *Circ Res* 2014; 115: 165–175.

9. Humbert M, Guignabert C, Bonnet S, et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. *Eur Respir J* 2019; 53(1): 1801887.

10. Tian W, Jiang X, Sung YK, et al. Leukotrienes in pulmonary arterial hypertension. *Immunol Res* 2014; 58: 387–393.

11. Kuhn H, Banthiya S and van Leyen K. Mammalian lipoxygenases and their biological relevance. *Biochim Biophys Acta* 2017; 1861(7): 1148–1166.

12. Xia W, Xie L, Cao B, et al. Genes involved in leukotriene synthesis pathway are dynamically regulated during lung development in Rhesus monkeys. *Prostaglandins Leukot Essent Fatty Acids* 2017; 122: 1–6.

13. Woods JW, Evans JF, Ethier D, et al. 5-Lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes. *J Exp Med* 1993; 178: 1935–1946.

14. Woods JW, Coffey MJ, Brock TG, et al. 5-Lipoxygenase is located in the euchromatin of the nucleus in resting human alveolar macrophages and translocates to the nuclear envelope upon cell activation. *J Clin Invest* 1995; 95: 2035–2046.

15. Dahlen SE, Hedqvist P, Westlund P, et al. Mechanisms of leukotriene-induced contractions of guinea pig airways: leukotriene C4 has a potent direct action whereas leukotriene B4 acts indirectly. *Acta Physiol Scand* 1983; 118: 393–403.

16. Peters-Golden M and Henderson WR Jr. Leukotrienes. *N Engl J Med* 2007; 357: 1841–1854.

17. Kowal-Bielecka O, Chwiesko-Minarowska S, Bernatowicz PL, et al. The arachidonate 5-lipoxygenase activating protein gene polymorphism is associated with the risk of scleroderma-related interstitial lung disease: a multicentre European Scleroderma Trials and Research group (EUSTAR) study. *J Rheumatol* 2015; 37: 1841–1854.

18. Li Y, Xu X, Zhang D, et al. Genetic variation in the leukotriene pathway is associated with myocardial infarction in the Chinese population. *Lipids Health Dis* 2019; 18: 25.

19. Van Sambeek R, Stevenson DD, Baldasaro M, et al. 5' flanking region polymorphism of the gene encoding leukotriene C4 synthase does not correlate with the aspirin-intolerant asthma phenotype in the United States. *J Allergy Clin Immunol* 2000; 106: 72–76.

20. Hong X, Zhou H, Tsai HJ, et al. Cysteinyl leukotriene receptor 1 gene variation and risk of asthma. *Eur Respir J* 2009; 33: 42–48.

21. McDonnell TJ, Chang SW, Westcott JY, et al. Role of oxidants, eicosanoids, and neutrophils in amphoterin B lung injury in rats. *J Appl Physiol* 1988; 65: 2195–2206.

22. Bäck M. Studies of receptors and modulatory mechanisms in functional responses to cysteinyl-leukotrienes in smooth muscle. *Acta Physiol Scand Suppl* 2002; 648: 1–55.

23. Hui Y and Funk CD. Cysteinyl leukotriene receptors. *Biochem Pharmacol* 2002; 64: 1549–1557.

24. Capra V, Carnini C, Accomazzo MR, et al. Autocrine activity of cysteinyl leukotrienes in human vascular endothelial cells: signaling through the CysLT2 receptor. *Prostaglandins Other Lipid Mediat* 2015; 120: 115–125.

25. Malmsten CL, Palmblad J, Udén AM, et al. Leukotriene B4: a highly potent and stereospecific factor stimulating migration of polymorphonuclear leukocytes. *Acta Physiol Scand* 1980; 110: 449–451.

26. Liu X, Yang T, Mao L, et al. Leukotriene B4 inhibits L-type calcium channels via P38 signaling pathway in vascular smooth muscle cells. *Cell Physiol Biochem* 2015; 37: 1903–1913.

27. Qian J, Tian W, Jiang X, et al. Leukotriene B4 activates pulmonary artery adventitial fibroblasts in pulmonary hypertension. *Hypertension* 2015; 66: 1227–1239.

28. Park MK, Park Y, Shim J, et al. Novel involvement of leukotriene B2 receptor 2 through ERK activation by PP2A down-regulation in leukotriene B2-induced keratin phosphorylation and reorganization of pancreatic cancer cells. *Biochim Biophys Acta* 2012; 1823: 2120–2129.

29. Ee MT, Kantores C, Ivanovska J, et al. Leukotriene B4 induces macrophage influx and pulmonary hypertension in bleomycin-induced chronic neonatal lung injury. *Am J Physiol Lung Cell Mol Physiol* 2016; 311: L292–L302.

30. Kageyama Y, Koide Y, Miyamoto S, et al. Leukotriene B4-induced interleukin-1 beta in synovial cells from patients with rheumatoid arthritis. *Rheumatol* 1994; 23: 148–150.

31. Percher F, Curis C, Pérès E, et al. HTLV-1-induced leukotriene B4 secretion by T cells promotes T cell recruitment and virus propagation. *Nat Commun* 2017; 8: 15890.

32. Lee W, Su Kim H and Lee GR. Leukotrienes induce interleukin-1 in cervical organ primary human myometrial cells. *Cell Tissues Organs* 2016; 201: 319–320.

33. Patpathy SR, Jala VR, Bodduluri SR, et al. Crystalline silica-induced leukotriene B4-dependent inflammation promotes lung tumour growth. *Nat Commun* 2015; 6: 70.

34. Houang YH, Sharifpanah F, Becker S, et al. Impact of arachidonic acid and the leukotriene signaling pathway on vascularogenesis of mouse embryonic stem cells. *Cells Tissues Organs* 2016; 201: 319–320.

35. Park MK, Park Y, Shim J, et al. Novel involvement of leukotriene B4 receptor 2 through ERK activation by PP2A
down-regulation in leukotriene B4-induced keratin phosphorylation and reorganization of pancreatic cancer cells. *Biochim Biophys Acta* 2012; 1823: 2120–2129.

36. Salim T, Sand-Dejmek J and Sjölander A. The inflammatory mediator leukotriene D4 induces subcellular β-catenin translocation and migration of colon cancer cells. *Exp Cell Res* 2014; 321: 255–266.

37. Myers CE and Ghosh J. Lipoxigenase inhibition in prostate cancer. *Eur Urol* 1999; 35: 395–398.

38. Ra˚dmark O and Samuelsson B. 5-Lipoxygenase: mechanisms of regulation. *J Lipid Res* 2009; 50: S40–S45.

39. Voelkel NF, Mechanisms of hypoxic pulmonary vasoconstriction. *Am Rev Respir Dis* 1986; 133: 1186–1195.

40. Voelkel NF, Tuder RM, Wade K, et al. Inhibition of 5-lipoxygenase production following sequestration of neutrophils in isolated lungs: indirect evidence for intercellular leukotriene A4 transfer. *Blood* 1988; 72: 1687–1692.

41. Murphy RC, Hammarstro ¨m S and Samuelsson B. Leukotriene C4 production during hypoxic pulmonary vasoconstriction in rats. *Am Rev Respir Dis* 1984; 130: H859–H866.

42. Wright L, Tuder RM, Wang J, et al. 5-Lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension. *Am J Respir Crit Care Med* 1998; 157: 219–229.

43. Zhang YY, Walker JL, Huang A, et al. Expression of 5-lipoxygenase in pulmonary artery endothelial cells. *Biochem J* 2002; 361: 267–276.

44. Jones JE, Walker JL, Song Y, et al. Effect of 5-lipoxygenase on the development of pulmonary hypertension in rats. *Am J Physiol Heart Circ Physiol* 2004; 286: H1775–H1784.

45. Song Y, Jones JE, Beppu H, et al. Increased susceptibility to pulmonary hypertension in heterozygous BMPR2-mutant mice. *Circulation* 2005; 112: 553–562.

46. Al-Husseini A, Wijesinghe DS, Farkas L, et al. Increased eicosanoid levels in the Sugen/chronic hypoxia model of severe pulmonary hypertension. *PLoS One* 2015; 10(3): e0120157.

47. Fairweather D and Frisancho-Kiss S. Mast cells and inflammation and arachidonate metabolism in monocrotaline-induced pulmonary hypertension. *Pulmonary Circulation* 2010 Number 1 | 7

48. Peters-Golden M and Brock TG. Intracellular compartmentalization of leukotriene synthesis: unexpected nuclear secrets. *FEBS Lett* 2001; 487: 323–326.

49. Brock TG. Regulating leukotriene synthesis: the role of nuclear 5-lipoxygenase. *J Cell Biochem* 2005; 96: 1203–1211.

50. Brock TG, Maydanski E, McNish RW, et al. Co-localization of leukotriene a4 hydrolase with 5-lipoxygenase in nuclei of alveolar macrophages and rat basophilic leukemia cells but not neutrophils. *J Biol Chem* 2005; 289(2): L224–32.
74. Healy AM, Peters-Golden M, Yao JP, et al. Identification of a bipartite nuclear localization sequence necessary for nuclear import of 5-lipoxygenase. *J Biol Chem* 1999; 274: 29812–29818.

75. Häfner AK, Kahnt AS and Steinhilber D. Beyond leukotriene formation. The noncanonical functions of 5-lipoxygenase. *Prostaglandins Other Lipid Mediat* 2019; 142: 24–32.

76. Lepley RA and Fitzpatrick FA. 5-Lipoxygenase compartmentalization in granulocytic cells is modulated by an internal bipartite nuclear localizing sequence and nuclear factor kappa B complex formation. *Arch Biochem Biophys* 1998; 356: 71–76.

77. Shi R, Zhu D, Wei Z, et al. Baicalein attenuates monocrotaline-induced pulmonary arterial hypertension by inhibiting endothelial-to-mesenchymal transition. *Life Sci* 2018; 207: 442–450.

78. Pullamsetti SS, Kojonazarov B, Storn S, et al. Lung cancer-associated pulmonary hypertension: role of microenvironmental inflammation based on tumor cell-immune cell cross-talk. *Sci Transl Med* 2017; 9(416): eaai9048.

79. Elinoff JM, Chen LY, Dougherty EJ, et al. Spironolactone-induced degradation of the TFIIH core complex XPB subunit suppresses NF-κB and AP-1 signalling. *Cardiovasc Res* 2018; 114: 65–76.

80. Patel H, Zaghoul N, Lin K, et al. Hypoxia-induced activation of specific members of the NF-kB family and its relevance to pulmonary vascular remodeling. *Int J Biochem Cell Biol* 2017; 92: 141–147.

81. Brogliato AR, Moor AN, Kesl SL, et al. Critical role of 5-lipoxygenase and heme oxygenase-1 in wound healing. *J Invest Dermatol* 2014; 134: 1436–1445.

82. Cummings M, Massey KA, Mappa G, et al. Integrated eicosanoid lipidomics and gene expression reveal decreased prostaglandin catabolism and increased 5-lipoxygenase expression in aggressive subtypes of endometrial cancer. *J Pathol* 2019; 247: 21–34.

83. Reyes I, Reyes N, Suriano R, et al. Gene expression profiling identifies potential molecular markers of papillary thyroid carcinoma. *Cancer Biomark* 2019; 24: 71–83.

84. Jala VR, Bodduleri SR, Satpathy SR, et al. The yin and yang of leukotriene B4 mediated inflammation in cancer. *Semin Immunol* 2017; 33: 58–64.

85. Duah E, Teegala LR, Kondeti V, et al. Cysteinyl leukotriene 2 receptor promotes endothelial permeability, tumor angiogenesis, and metastasis. *Proc Natl Acad Sci U S A* 2019; 116: 199–204.

86. Yektai-Karin E, Zovko A, Nilsson A, et al. Modulation of leukotriene signaling inhibiting cell growth in chronic myeloid leukemia. *Leuk Lymphoma* 2017; 58: 1903–1913.

87. Khopfai S, Thanee M, Techasen A, et al. Zileuton suppresses cholangiocarcinoma cell proliferation and migration through inhibition of the Akt signaling pathway. *Onco Targets Ther* 2018; 11: 7019–7029.

88. Fischer AS, Metzner J, Steinbrink SD, et al. 5-Lipoxygenase inhibitors induce potent anti-proliferative and cytotoxic effects in human tumour cells independently of suppression of 5-lipoxygenase activity. *Br J Pharmacol* 2010; 161: 936–949.

89. Kumar R, Coronel L, Somalanka B, et al. Mitochondrial uncoupling reveals a novel therapeutic opportunity for p53-defective cancers. *Nat Commun* 2018; 9: 3931.

90. Sarveswaran S, Varma NRS, Morissetty S, et al. Inhibition of 5-lipoxygenase downregulates stemness and kills prostate cancer stem cells by triggering apoptosis via activation of c-Jun N-terminal kinase. *OncoTarget* 2019; 10: 424–436.

91. Ringleb J, Strack E, Angioni C, et al. Apoptotic cancer cells suppress 5-lipoxygenase in tumor-associated macrophages. *J Immunol* 2018; 200: 857–868.

92. Kiss L, Schütte H, Mayer K, et al. Synthesis of arachidonic acid-derived lipoxigenase and cytochrome P450 products in the intact human lung vasculature. *Am J Respir Crit Care Med* 2000; 161: 1917–2376.

93. Voelkel NF, Gomez-Arroyo J, Abbate A, et al. Pathobiology of pulmonary arterial hypertension and right ventricular failure. *Eur Respir J* 2012; 40: 1555–1565.

94. Bu X, Wang C and Pang B. Effects of leukotriene receptor antagonist on chronic obstructive [correction of obstractive] pulmonary disease induced pulmonary hypertension. *Chin Med J (Engl)* 2003; 116: 459–461.

95. Scott JP and Peters-Golden M. Antileukotriene agents for the treatment of lung disease. *Am J Respir Crit Care Med* 2013; 188: 538–544.